Palvella Therapeutics, Inc. (PVLA) compared with its closest peers (XLO, CPIX, AQST, NUVL, ENVB). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Xilio Therapeutics, Cumberland Pharmaceuticals, Aquestive Therapeutics, Nuvalent, Enveric Biosciences, KalVista Pharmaceuticals, Lexicon Pharmaceuticals, Verrica Pharmaceuticals, Ocular Therapeutix and XOMA Royalty share Palvella Therapeutics's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Xilio Therapeutics, Inc. (XLO) | $52.68M | -0.2 |
| Cumberland Pharmaceuticals Inc. (CPIX) | $114.10M | -20.5 |
| Aquestive Therapeutics, Inc. (AQST) | $583.63M | -8.4 |
| Nuvalent, Inc. (NUVL) | $9.75B | -17.2 |
| Enveric Biosciences, Inc. (ENVB) | $6.36M | -0.1 |
| KalVista Pharmaceuticals, Inc. (KALV) | $1.44B | -8.0 |
| Lexicon Pharmaceuticals, Inc. (LXRX) | $1.03B | -8.1 |
| Verrica Pharmaceuticals Inc. (VRCA) | $83.15M | -5.0 |
| Ocular Therapeutix, Inc. (OCUL) | $2.43B | -8.5 |
| XOMA Royalty Corp. (XOMA) | $505.65M | 16.8 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
PVLA overview · PVLA earnings · PVLA financials · PVLA KPIs · PVLA documents · PVLA ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.